MFE-280 Xenograft Model Service for Endometrial Cancer

Alfa Cytology offers the MFE-280 Xenograft Model Service for Endometrial Cancer, a robust preclinical platform for evaluating therapeutic efficacy against recurrent endometrial adenocarcinoma. Leveraging validated cell line authentication and standardized protocols, Alfa Cytology delivers reproducible tumor growth data to accelerate your drug development pipeline from lead optimization to IND-enabling studies.

Overview of MFE-280 Xenograft Model for Endometrial Cancer

The MFE-280 xenograft model is established from a human endometrial adenocarcinoma cell line originally derived from a recurrent, poorly differentiated tumor in a 78-year-old patient. This cell line exhibits near-diploid karyotype with complex heterogeneous aberrations, expresses progesterone receptors, and demonstrates robust tumorigenicity in immunodeficient mice, making it a clinically relevant surrogate for aggressive endometrial carcinoma subtypes. MFE-280 cells maintain epithelial-like morphology in monolayer culture and express canonical markers including cytokeratins 8, 18, and 19, vimentin, and placental protein 14 (PP14), reflecting their endometrial origin and differentiated phenotype.

In preclinical oncology, the MFE-280 xenograft serves as a critical tool for investigating tumor biology, drug response, and resistance mechanisms in endometrial cancer. The model supports subcutaneous or orthotopic implantation strategies, enabling longitudinal tumor monitoring through caliper measurements or bioluminescence imaging when luciferase-reporter derivatives are employed. Researchers utilize this platform to evaluate cytotoxic agents, hormonal therapies, targeted small molecules, and immunotherapy combinations, benefiting from the model's ability to recapitulate histopathological features of the parental tumor and its documented responsiveness to standard-of-care references.

Figure 1. The effects of pharmacological agents (AQP channel inhibitors) on EC cell line invasion. (Khan, Sidra, et al., 2023)

Cell Line Information: MFE-280

The MFE-280 cell line is a well-characterized human endometrial adenocarcinoma model established from tumor tissue of a 77- to 78-year-old woman with recurrent carcinoma (adenomatous, partly papillary, grade G3) in 1990. The cells were initially cultured as suspension aggregates for one year before adaptation to monolayer growth, and they retain the capacity to form heterotransplantable tumors in nude mice. Below is a comprehensive summary of the cell line characteristics.

Our Services

Alfa Cytology specializes in preclinical tumor model services and offers comprehensive MFE-280 xenograft model development tailored to your therapeutic program. From initial cell line expansion and quality control to in vivo implantation, tumor monitoring, and endpoint analysis, our integrated platform ensures high-fidelity data generation for endometrial cancer drug discovery and development projects.

Workflow of MFE-280 Xenograft Model Construction

The construction of the MFE-280 xenograft model follows a standardized, multi-step workflow designed to ensure reproducible tumor growth and reliable pharmacological readouts. Each stage incorporates rigorous quality control measures to maintain cell line integrity, animal welfare standards, and data consistency across study cohorts.

1. Cell Line Expansion and Authentication: MFE-280 cells are revived from cryopreserved stocks and expanded under optimized culture conditions. Cells are authenticated by STR profiling to confirm identity, tested for mycoplasma contamination, and assessed for viability and morphology prior to implantation.
2. Pre-Implantation Preparation: Cultures are harvested at logarithmic growth phase using standardized dissociation protocols. Cell suspensions are prepared in serum-free medium or Matrigel mixtures at defined concentrations, typically 5 x 10^6 to 1 x 10^7 cells per injection site, to ensure consistent engraftment rates.
3. Animal Selection and Implantation: Immunodeficient mouse strains (e.g., NOD-SCID or nude mice) are selected based on study objectives and maintained under pathogen-free conditions. MFE-280 cells are implanted subcutaneously into the flank or orthotopically into the uterine horn, depending on the desired tumor microenvironment and metastasis modeling requirements.
4. Tumor Monitoring and Growth Assessment: Tumor dimensions are measured twice weekly using digital calipers, and volumes are calculated via the ellipsoid formula (length x width^2 x 0.5). For luciferase-expressing MFE-280 derivatives, bioluminescence imaging is performed weekly to monitor tumor burden and spatial distribution non-invasively.
5. Study Cohort Randomization and Treatment: Upon reaching a predefined tumor volume (typically 100-200 mm^3), animals are randomized into treatment and vehicle control groups. Test articles are administered according to the study protocol, with dosing schedules optimized for pharmacokinetic and pharmacodynamic endpoints.
6. Endpoint Analysis and Sample Collection: At study termination, tumors are excised, weighed, and processed for histopathological, immunohistochemical, or molecular analysis. Peripheral blood, plasma, and critical organs are collected to evaluate systemic toxicity, biomarker modulation, and pharmacokinetic parameters.

Figure 2: Schematic workflow illustrating the derivation and construction of the MFE-280 Xenograft Model at Alfa Cytology.

Case Study-MFE-280 Xenograft Model Development

In a representative engagement, Alfa Cytology developed a subcutaneous MFE-280 xenograft model to support a client's endometrial cancer therapeutic program. Following cell line authentication and expansion, immunodeficient mice were implanted with MFE-280 cells, achieving consistent engraftment with tumor volumes reaching evaluable thresholds within 2-3 weeks post-implantation. The model demonstrated dose-dependent response to reference cytotoxic and hormonal agents, providing robust pharmacodynamic data that informed the client's candidate selection strategy. Tumor tissues retained histological features consistent with poorly differentiated endometrial adenocarcinoma, including epithelial marker expression and stromal infiltration patterns, validating the translational relevance of the platform for subsequent IND-enabling studies.

Why Choose Alfa Cytology?

Alfa Cytology provides a fully integrated preclinical service platform for endometrial cancer xenograft model development, combining rigorous scientific execution with operational flexibility to meet diverse program requirements.

• Validated Cell Line Repository: All MFE-280 cells are authenticated by STR profiling and routinely tested for mycoplasma to ensure genetic integrity and experimental reproducibility.
• Customized Study Design: Protocols are tailored to specific therapeutic modalities, including cytotoxic agents, hormonal therapies, targeted inhibitors, and immuno-oncology combinations.
• Comprehensive Endpoint Capabilities: We offer tumor growth monitoring, survival analysis, biomarker quantification, histopathology, immunohistochemistry, and pharmacokinetic/pharmacodynamic integration.
• Regulatory-Compliant Operations: Studies are conducted under IACUC-approved protocols with documented standard operating procedures to support IND submission and regulatory filings.
• Dedicated Project Management: Each engagement is supported by a scientific project manager ensuring transparent communication, milestone tracking, and timely delivery of study reports.

Contact us

Ready to advance your endometrial cancer therapeutic program with a validated MFE-280 xenograft model? Contact us today to discuss your project requirements, receive a customized study proposal, and learn how Alfa Cytology can accelerate your preclinical development timeline. Reach out to our scientific team to explore how our MFE-280 Xenograft Model Service for Endometrial Cancer can deliver the robust, translational data you need to move confidently into clinical development.

For research use only. Not intended for any clinical use.